Press Room

Press Clipping / Nov 25, 2024

Pharma company Hovione to double capacity at Cork site as part multi-million euro investment

Irish Examiner, 25 November 2024

Pharmaceutical contract development and manufacturing company Hovione has officially commissioned an expansion at its manufacturing facility in Ringaskiddy, Cork. 

Announcing the development on Monday, the multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions.

This manufacturing technology is especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments, the company said.

Deputising for the Mayor of the County of Cork, Cllr. Audrey Buckley said: “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today. 

"It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.” 

Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law said: “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector.

"I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”.

This latest investment builds on the momentum of the recently announced spray drying capacity expansion at the Company's East Windsor, New Jersey, site. 

Jean-Luc Herbeaux, Hovione´s Chief Executive said: “This newly opened facility further strengthens Hovione´s position as the global CDMO of choice for spray drying development and manufacturing services. 

"It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.”

IDA chief executive Michael Lohan said the company has made a significant contribution both locally and nationally, adding: "I am pleased to be here today to mark another step on that journey. We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success.”

 

Read the full article on IrishExaminer.com

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026